EuroBiotech—More articles of note


> Oculis raised CHF 20 million ($20 million) from backers including Novartis. The Swiss biotech will use the money to advance a phase 2b diabetic macular edema drug. Statement

> Themis raised €10 million ($12 million). The series C gives Themis the means to advance its pipeline of vaccines, including a phase 2 chikungunya virus candidate. Release

> Addex Therapeutics entered into a licensing agreement with Indivior for addiction drug ADX71441. Indivior is paying $5 million (€4 million) upfront and committing to up to $330 million in milestones to buy into the program. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Galapagos shared an update on its cystic fibrosis programs. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.